Enhancing cancer targeting of γ9δ2TCR through modified NKG2D co-stimulation
P. Hernandez-Lopez, E. van Diest, I. Johanna, S. Heijhuurs, T. Straetemans, Z. Sebestyen, D. X. Beringer, J. Kuball
This paper improves the antitumor activity of TEG001 by co-expressing NKG2D-based chimeric co-receptors with the {gamma}{delta}TCR-Cl5.
bioRxiv · Jan 6, 2021 · PreprintImmunology